Clinical trials: Schizophrenia Patients
Schizophrenia
Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
The study aims to investigate the modulation of regional brain activation in schizophrenic patients by psychopharmacological treatment with either haloperidol, amisulpride or olanzapine.
- Trial name
- NCT00419653
- Testing
- Amisulpride, Olanzapine, Haloperidol
- Volunteers
- 19 people
- Sponsor
- University of Jena
Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia
This study is an exploratory proof of mechanism (POM) study using PET/functional magnetic resonance imaging (fMRI) in a 2-period, 2-sequence, crossover design.
- Trial name
- NCT06880328
- Testing
- Ralmitaront, Radiolabeled PET tracer [18F]-DOPA
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Diabetes, Hypertension
Pharmacy Interventions to Improve Chronic Disease Medication Refill
Compare the effectiveness of 3 strategies by pharmacists to decrease the time to refill of prescriptions for common chronic diseases (diabetes, hypertension, hyperlipidemia, heart failure, depression, psychoses).
- Conditions
- Diabetes, Hypertension, Hyperlipidemia, Heart Diseases
- Trial name
- NCT00469365
- Testing
- pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
- Where
- United States
- Volunteers
- 3,048 people
- Sponsor
- Medical University of South Carolina
Schizophrenia
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia
This Study is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Fixed-Dose, Phase 3 Clinical Trial Evaluating the Efficacy and Safety of WID-RGC20 3 mg/day and 6 mg/day in Patients with Acute Psychotic…
- Trial name
- NCT05168007
- Testing
- WID-RGC20(Cariprazine) 3mg/day, WID-RGC20(Cariprazine) 6mg/day
- Where
- South Korea
- Volunteers
- 342 people
- Sponsor
- Whanin Pharmaceutical Company
Psychosis, Schizophrenia
Cognitive Behavioral Therapy for Patients With an Early Psychosis
The purpose of the present study is to examine whether cognitive behavior therapy will reduce depressive symptoms and increase self-esteem for patients with a first episode psychosis.
- Conditions
- Psychosis, Schizophrenia, Depressive Symptoms, Self-esteem
- Trial name
- NCT01511406
- Testing
- cognitive behavioral therapy
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Schizophrenia
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of multiple ascending oral doses of ASP4345 in patients with schizophrenia.
- Trial name
- NCT02720263
- Testing
- ASP4345
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Schizophrenia
Inpatient Evaluation of Adults With Schizophrenia
The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness.
- Trial name
- NCT00001247
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
This study will use single photon emission computed tomography (SPECT) to study brain nicotine receptors (proteins on the surface of brain cells) in healthy subjects and in patients with schizophrenia.
- Trial name
- NCT00061789
- Testing
- SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Psychotic Disorders, Cannabis Use Disorder
RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders
The goal of this clinical trial is to conduct a single-blind randomized controlled trial to verify whether the Avatar Intervention has greater efficacy over supportive intervention to reduce cannabis use in patients with…
- Conditions
- Psychotic Disorders, Cannabis Use Disorder, Mental Health Disorder
- Trial name
- AC2 (NCT05704582)
- Testing
- Avatar Intervention, Addiction supportive intervention
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Schizophrenia
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.
- Trial name
- NCT01892384
- Testing
- BI 409306
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, Anxiety-comorbidity to Schizophrenia
Pregablin for Anxiety-comorbidity in Patients With Schizophrenia
The PACS study aims to investigate the efficacy and tolerability of pregabalin for schizophrenic patients that suffer from comorbid anxiety. The study design is an 8 week flexible dosage, randomized placebo controlled.
- Trial name
- PACS (NCT01496690)
- Testing
- Pregabalin
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- University of Aarhus
Schizophrenia
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent…
- Trial name
- NCT00616798
- Testing
- RO4917838, Standard antipsychotic therapy
- Where
- 73 sites in United States, Austria and 8 more
- Volunteers
- 323 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
- Trial name
- NCT03793712
- Testing
- Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day)
- Where
- 53 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 168 people
- Sponsor
- H. Lundbeck A/S
Chronic Schizophrenia
A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or…
- Trial name
- NCT02624167
- Testing
- NW-3509A
- Where
- 5 sites in United States, India
- Volunteers
- 90 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
This study will investigate the safety, tolerability, PK and PD profile of AUT00206 after repeated doses in patients with stable but symptomatic schizophrenia, taking one or two established anti-psychotic drugs.
- Trial name
- NCT03164876
- Testing
- AUT00206
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Autifony Therapeutics Limited
Schizophrenia, Psychoses
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
Prodrome based early intervention with an antipsychotic drug vs. benzodiazepine was applied in patients with first episode schizophrenia after one year neuroleptic maintenance treatment.
- Trial name
- NCT00159133
- Testing
- antipsychotics vs. Lorazepam (Drugs)
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia Disorder
Virtual Reality-Based Smoking Cessation Treatment in Patients With Schizophrenia
Schizophrenia is associated with high rates of cigarette smoking, which contributes to serious physical health problems and reduced life expectancy.
- Trial name
- NCT07618338
- Testing
- Schizophrenia VR Intervention Group, Healthy Control VR Intervention Group
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University
Schizophrenia
Clozapine and Olanzapine Treatment of Aggression
This was a double-blind randomized study with three treatment arms: clozapine, olanzapine and haloperidol. We compared these three medications in the treatment of aggressive behavior over a 12 week period.
- Trial name
- NCT01123408
- Testing
- Clozapine, Olanzapine, Haloperidol
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Psychosis
Effects of Transcranial Direct Current Stimulation (tDCS) on Motor Function in Schizophrenia Patients and Individuals at Risk for Psychotic Onset
The purposes of this research are to investigate (1) if schizophrenia patients and at-risk individuals present bradykinesia and dyskinesia and (2) if tDCS improves motor performance in schizophrenia patients and at-risk…
- Conditions
- Schizophrenia, Psychosis, Parkinsonism, Dyskinesias
- Trial name
- NCT04086160
- Testing
- Transcranial direct current stimulation device (Soterix Medical, New York, NY)
- Where
- Hong Kong
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dr WANG Shumei